JOURNAL OF EMERGING AND RARE DISEASES (ISSN:2517-7397)

Biography:

Prof. Vladan Bajic was born in Switzerland, 1961. He graduated in 1986 School of Veterinary Medicine and in 1992 became a Research Scientist for Animal Experimental Medicine in Galenika Pharmaceutical Company, Institute for Pharmaceutical Research, Biomedical Department, Belgrade, Serbia. In 1998 he completed his MSc in Genetic Toxicology and my Ph.D. in 2002, in CytopathoGenetics, on the genotoxic relevance of Centromere Instability *(CIN) in Normal Cells exposed to Cytostatics. This has lead to my present and future interest in Alzheimer’s Disease through the finding that CIN is present in AD patients. Still. He also worked on my managerial skills and became Director of Biomedical Research in Galenika Pharmaceuticals in 2003. In 2004 I became Assistant General Manager for R and D and a member of the Board of Directors, Galenika Pharmaceuticals. In 2007 he returned to his Research and he was awarded a Fulbright Scholarship for Alzheimer’s Research. In 2011, he was awarded German Scholar Program DAAD for AD research. Both programs were related to CIN in AD. In 2012 I became Full Professor of Research. From 2013 to date at the Institute for Nuclear Research ‘’Vinca’’, Department of molecular genetics he is working on the role of late phase cell cycle proteins in AD.

Research Interests:

Expression patterns of late core cell cycle proteins in neurodegeneration (APC,Mad2b, BubR1, Cohesin, CDK 11) especially in Aging and Alzheimer’s Disease, X chromosome instability phenotype in AD, interested in X chromosome territories in neurons, iPSC stem cell system for modelling Alzheimer’s disease and evaluating the role of X chromosome inactivation patterns in cells affected by APP mutations, Investigation of prevention strategies for oxidative stress in aging by using plant extracts (especially olive dry leaf extract). protein-DNA associations by using bioinformatic tools. Also, trying to discern miRNA networks in overlapping diseases, such as AD vs AMD, AD vs Cancer and AD vs HF (Heart Failure)